Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7297089 in Relapsed or Refractory Multiple Myeloma
NCT04434469Phase 1Completed
- Sponsor
- Genentech
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of RO7297089 in multiple myeloma (MM) (2 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events (AEs), Including Dose Limiting Toxicities (DLTs). Started Jul 2020; status: completed.
02
Drugs
RO7297089
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04434469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04434469.